DGAP-Adhoc
WILEX AG: WILEX signs antibody license agreement with Telix Pharmaceuticals Limited
DGAP-Ad-hoc: WILEX AG / Key word(s): Alliance
Ad-hoc announcement |
Inside information according to Article 17 MAR
WILEX signs antibody license agreement with Telix Pharmaceuticals Limited
Munich, Germany, 16 January 2017 - WILEX AG (ISIN DE000A11QVV0 / WL6 / FSE)
and Australian biopharmaceutical company Telix Pharmaceuticals Limited
("Telix"), today announced that they have concluded a worldwide license
agreement for the development and commercialization of the imaging agent
REDECTANE(R), a radiolabeled form of the monoclonal antibody Girentuximab.
WILEX successfully completed a first Phase III trial with REDECTANE(R) in
ccRCC.
WILEX has granted Telix the worldwide licensing rights to further develop
and commercialize the REDECTANE(R) molecular imaging program. Under the
agreement, Telix will, as a first step, invest in an improved manufacturing
process for the antibody. Under the terms of the agreement, WILEX is
eligible to receive up-front and milestone payments totaling USD 3.7
million. In addition, WILEX is eligible to receive significant royalties on
global net sales of REDECTANE(R), commensurate with a Phase III asset.
Telix will be responsible for all development costs, as well as
manufacturing and commercialization costs.
Telix will also develop a therapeutic radioimmunoconjugate program based on
Girentuximab. Early clinical data suggests that 177Lu-labeled Girentuximab
has disease stabilizing effects in patients with advanced staged metastatic
renal cancer. Telix is evaluating the use of CAIX targeting therapeutic
agents with both beta- and alpha-emitting radionuclides for a variety of
malignancies. Under the terms of the agreement, if a therapeutic product
developed by Telix is ultimately granted marketing approval, WILEX will
receive single-digit royalties.